By Reed R. Kathrein

The Subpoena in the Drawer

There is a fundamental operating premise in public markets that clinical-stage biotechnology companies often treat as an optional technicality: you are allowed to test drugs that do not work out, and you are allowed to conduct trials where biology refuses to cooperate, but you are not permitted to assure public market investors that your compound is physically incapable of poisoning the body while watching it do precisely that. The entire business model of small-molecule drug development involves taking speculative shots at human biology, which is notoriously indifferent to investor pitch decks. When clinical reality diverges from the prospectus, corporate management faces an age-old choice: take the immediate pricing hit, or spin a comforting tale about pristine safety margins until the Food and Drug Administration steps in to do it for you.

Aardvark Therapeutics, Inc. (NASDAQ: AARD) took public capital on the back of a particularly clean narrative. The company pitched its lead asset, ARD-101, as a gut-restricted wonder designed to treat hyperphagia—the relentless, insatiable hunger associated with Prader-Willi Syndrome. The core selling point was not merely that it worked, but that it was practically an engineering marvel of biological containment: because it supposedly acted like a "topical" agent for the intestines, virtually none of it entered the bloodstream, leaving zero footprint for systemic toxicity. If none of the drug reaches general circulation, you do not have to worry about cardiac side effects. It was an elegant story, and the public paid $16.00 a share in the company’s IPO to hear it.

The Mechanics of the Mirage

The financial plumbing of early-stage biotech relies on creating an unbroken runway of valuation milestones. You raise $87.6 million in an initial public offering, as Aardvark did, beginning with the IPO documents  by telling the street that your Phase 2 data is spotless, your Phase 3 HERO trial is aligned with regulators as a single pivotal study, and the compound is 99% restricted to the lumen of the gut. If Wall Street believes that systemic absorption is less than 1%, analysts do not discount the share price for cardiac risks; they model smooth regulatory clearance and issue glowing price targets.

The problem arose when human bodies interacted with the compound outside the narrative boundary. Far from remaining neatly locked inside the gut wall, ARD-101 demonstrated clear systemic consequences, according to the complaint filed in Wonderly v. Aardvark Therapeutics, Inc., Case No. 3:26-cv-04643-BJC-GC, in the U.S. District Court for the Southern District of California. In routine safety monitoring during a healthy volunteer study, participants dosing the compound exhibited reversible QRS prolongation—an electrical disruption in the heart's ventricles—directly correlated to blood plasma concentrations. When Aardvark announced a "voluntary pause" on February 27, 2026, the stock collapsed 56.2% overnight to $5.47. When the FDA intervened on May 14, 2026, by slamming the brakes with a full clinical hold across all IND trials, the stock surrendered another 32.1% to hit $4.57.

The Texts

The paper trail here does not consist of back-alley deals; it lives in the stark, unvarnished public transcripts where executives went out of their way to explicitly rule out the exact disaster waiting in their data room. Speaking to institutional investors at the Morgan Stanley Global Healthcare Conference on September 8, 2025, Aardvark's Chief Executive Officer, Dr. Tien-Li Lee, offered this absolute masterclass in biological certainty:

Then, on February 27, 2026, Aardvark announced that it was pausing the HERO trial, attributing its decision to “cardiac observations at above target […] during routine safety monitoring[.]” By May 14, 2026, the company announced that the FDA put a full clinical hold on its investigational new drug application for ARD-101 concerning all HERO studies.

While what Aardvark executives knew and when is the question of the day, there is an enduring corporate impulse to convert an operational hypothesis into an absolute physical guarantee right up until the electrocardiograms print out the truth. When a biopharma executive assures an audience that systemic exposure is non-existent—specifically citing "cardiac toxins" as a non-issue—only to later report that healthy volunteers experienced >25% spikes in cardiac QRS intervals alongside a "clear blood plasma exposure-response relationship," the gap between marketing and chemistry ceases to be an academic debate. It becomes an actionable misstatement.

The Enforcement Deficit

The regulatory architecture cannot babysit every clinical presentation or recalculate plasma concentration charts across hundreds of development-stage issuers. The SEC does not possess the operational bandwidth to cross-examine Phase 2 safety decks against healthy volunteer telemetry in real time. By the time civil regulators catch up years down the road, executive options have vested and retail capital has evaporated. Fear Of Lawsuit (FOLS) remains the only mechanism imposing immediate, quantitative discipline on corporate officers who treat human pharmacology as an adjustable sales metric.

If You Bought the Float

If you happened to purchase $AARD securities during the period when management claimed ARD-101 had no systemic exposure and posed no cardiac liabilities, and you are interested in seeing the bill for that discrepancy, our litigation team at Hagens Berman is reviewing the paper trail.

• Case Hub: hbsslaw.com/AARD
• Email: [email protected]